Table 2. Details on Medication, Laboratory Workup, and Acute Recanalization Therapy According to the Selection Strategy Used.
| Measure | Total, No. | No. (%) | P value | ||
|---|---|---|---|---|---|
| DOAC plasma levels measured (n = 225) | Neither known levels nor idarucizumab (n = 355) | Idarucizumab (n = 252) | |||
| Age, median (IQR), y | 832 | 80 (73-87) | 79 (72-84) | 77 (71-83) | .005 |
| Sex | |||||
| Female | 832 | 111 (49.3) | 160 (45.1) | 84 (33.3) | <.001 |
| Male | 114 (50.7) | 195 (54.9) | 168 (66.7) | ||
| NIHSS score, median (IQR) | 828 | 10 (6-16) | 13 (7-18) | 10 (6-16) | .006 |
| Type of anticoagulation used | |||||
| Dabigatran | 832 | 15 (6.7) | 75 (21.1) | 252 (100) | <.001 |
| Rivaroxaban | 119 (52.9) | 139 (39.2) | 0 | ||
| Apixaban | 73 (32.4) | 90 (25.4) | 0 | ||
| Edoxaban | 18 (8.0) | 50 (14.1) | 0 | ||
| DOAC agent not specified | 0 | 1 (0.3) | 0 | ||
| Time from last ingestion to admission | |||||
| <12 h | 832 | 39 (17.3) | 73 (20.6) | 130 (51.6) | <.001 |
| 12-24 h | 48 (21.3) | 78 (22.0) | 32 (12.7) | ||
| 24-48 h | 43 (19.1) | 59 (16.6) | 1 (0.4) | ||
| Exact time point unknown but <48 h | 95 (42.2) | 145 (40.8) | 89 (35.3) | ||
| Time from last ingestion to admission, median (IQR), h | 503 | 14.4 (9-24) | 14 (9.51667-25) | 7 (4.75-11) | <.001 |
| International normalized ratio, median (IQR) | 674 | 1.1 (1-1.2) | 1.1 (1.02-1.2) | 1.13 (1.1-1.2) | .001 |
| Activated partial thrombin time, median (IQR), s | 664 | 29 (26-33) | 30 (27-34) | 37 (29-46) | <.001 |
| Thrombin time, median (IQR), s | 260 | 16.6 (15.2-18.3) | 14.6 (11.4-17.4) | 81.4 (43.9-120.0) | <.001 |
| DOAC plasma level, median (IQR), ng/mL | 244 | 21 (4.6-46) | NA | 83 (27-134) | NA |
| Type of intravenous thrombolysis used | |||||
| Alteplase | 831 | 223 (99.1) | 351 (99.2) | 206 (81.7) | <.001 |
| Tenecteplase | 2 (0.9) | 3 (0.8) | 46 (18.3) | ||
| Time from symptom onset to intravenous thrombolysis, median (IQR), h | 632 | 155 (105-230) | 145 (97-190) | 159 (120-202) | .03 |
| Mechanical thrombectomy | 832 | 79 (35.1) | 139 (39.2) | 67 (26.6) | .005 |
| Time from symptom onset to groin puncture, median (IQR), h | 199 | 188 (100-274) | 182 (148-225) | 296 (205-367) | <.001 |
| Symptomatic intracranial hemorrhage within 36 h | 832 | 7 (3.1) | 11 (3.1) | 3 (1.2) | .27 |
| Any hemorrhagic transformation within 36 h | 784 | 46 (20.5) | 79 (22.3) | 16 (7.8) | <.001 |
Abbreviations: DOAC, direct oral anticoagulant; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale.